UK markets closed

Mineralys Therapeutics, Inc. (MLYS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.00-0.15 (-1.14%)
At close: 04:00PM EDT
13.00 0.00 (0.00%)
After hours: 04:01PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 652.88M
Enterprise value 655.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.99
Enterprise value/revenue N/A
Enterprise value/EBITDA -24.25

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-15.22%
S&P500 52-week change 326.36%
52-week high 317.44
52-week low 35.85
50-day moving average 312.79
200-day moving average 310.92

Share statistics

Avg vol (3-month) 3145.13k
Avg vol (10-day) 3190.27k
Shares outstanding 549.65M
Implied shares outstanding 649.65M
Float 823M
% held by insiders 12.98%
% held by institutions 195.94%
Shares short (30 Apr 2024) 41.01M
Short ratio (30 Apr 2024) 49.47
Short % of float (30 Apr 2024) 42.99%
Short % of shares outstanding (30 Apr 2024) 42.04%
Shares short (prior month 28 Mar 2024) 4850.46k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.09%
Return on equity (ttm)-29.11%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-90.8M
Diluted EPS (ttm)-2.18
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)338.56M
Total cash per share (mrq)6.82
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)18.06
Book value per share (mrq)6.61

Cash flow statement

Operating cash flow (ttm)-87.54M
Levered free cash flow (ttm)-54.2M